Protocol Ledger

NCT04960930 · Phase III · COMPLETED

To Evaluate the Efficacy and Safety of Minocycline Hydrochloride Foam in the Treatment of Moderate-to-severe Acne Vulgaris

Interventional Phase III clinical trial protocol NCT04960930 sponsored by Cutia Therapeutics (Shanghai) Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-09-17 Enrollment: 372 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04960930
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)372 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04960930
Protocol FieldVerified Registry Value
NCT IdentifierNCT04960930
Consolidated Lead SponsorCutia Therapeutics (Shanghai) Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment372 participants (ACTUAL)
Registered Start Date2021-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI